Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995366 | 0.91 | KIF11 (0.43) | NR1H2NR1H3BRD4KIF11PTGDR2 | |
| SCHEMBL12875596 | 0.88 | KIF11 (0.49) | NR1H2NR1H3BRD4KIF11PTGDR2 | |
| SCHEMBL13995361 | 0.87 | PTGDR2 (0.43) | NR1H2NR1H3BRD4PTGDR2 | |
| SCHEMBL1190580 | 0.83 | KIF11 (0.47) | NR1H2NR1H3KIF11PTGDR2PTGS2 | |
| SCHEMBL1191536 | 0.82 | KIF11 (0.46) | NR1H2NR1H3KIF11PTGDR2PTGS2 | |
| SCHEMBL31716134 | 0.82 | KIF11 (0.46) | NR1H2NR1H3KIF11PTGDR2PTGS2 | |
| SCHEMBL3710331 | 0.82 | KIF11 (0.46) | NR1H2NR1H3KIF11PTGDR2PTGS2 | |
| SCHEMBL13995384 | 0.79 | KIF11 (0.44) | NR1H2NR1H3KIF11PTGDR2PTGS2 | |
| SCHEMBL13995370 | 0.78 | PTGDR2 (0.42) | NR1H2NR1H3PTGDR2 | |
| SCHEMBL12406512 | 0.75 | S1PR1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312229-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312229-A1 | Organic Compounds | DRD4, DRD1, SLC10A6 | NR1H2 945/4885NR1H3 842/4885BRD4 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.